Aaron Levitt

InvestorPlace Contributor

Aaron Levitt is an independent investment analyst and author living in State College, Pennsylvania. His work appears in several high profile publications in both print and on the web.

As an advocate for long-term globally oriented investing, Aaron believes that exchange traded funds have leveled playing field for Main Street. Following global macro-economic trends, investors now have several avenues to create great long term portfolios.

Aaron is a graduate of The Pennsylvania State University where he studied Economics and International Business. Aside for helping regular investors develop winning portfolios, his current projects include writing his first book on alternative energy investing.

Follow his picks and pans on Twitter at @AaronLevitt.

Recent Articles

5 Things to Think About Before Buying Exxon Stock

By Aaron Levitt, InvestorPlace Contributor Oct 16, 2018

Exxon stock is a huge bargain, but rivals are starting to catch up. The main thing to consider about Exxon is your personal timeline.

Amazon Adds to Its Value With Digital Ads

By Aaron Levitt, InvestorPlace Contributor Oct 16, 2018

Amazon is quickly going after Google and winning. Digital advertising is becoming a huge revenue and profit-driver for AMZN stock.

Rising Rates Are No Problem for These 5 ETFs

By Aaron Levitt, InvestorPlace Contributor Oct 9, 2018

These are some of the best ETFs to buy that can help limit the effects of higher rates, as the Federal Reserve continues to increase them.

5 Dividend Stocks to Buy for Growth as the Fed Raises Rates

By Aaron Levitt, InvestorPlace Contributor Sep 27, 2018

Just because the Fed is raising rates is no reason to dump dividend stocks. The key is in their ability to raise payouts. These 5 dividend stocks have proven to be great income growers over time.

5 Biotech Stocks to Play the Sector’s Next Big Trend: NASH

By Aaron Levitt, InvestorPlace Contributor Sep 26, 2018

Looking for blockbuster potential? These five biotech stocks may have found it in treating NASH -- an untapped market of up to $35 billion.